Investor Ideas Adds New Stocks
in #Biotech, #Tech and #Mining; (NasdaqGM: $EIGR), (NasdaqGM: $APEN),
(NasdaqGM: $PRTK),
(NasdaqGS: $CASA), (TSX: $BSR.V)
Point Roberts, WA, Delta BC – January 19, 2018 –
Investorideas.com, a global news source and leading investor resource covering
actively traded sectors announces this week’s additions to its global stock
directories in biotech, tech and mining.
Investorideas.com tracks companies in high-profile
trading sectors and makes ongoing additions to its stock directories for its members. Free previews of all
directories are available to the public with full login access only accessible
to members.
Read this news in full at http://www.investorideas.com/news/2018/main/01191Stocks.asp
The newest biotech additions are all Nasdaq-listed
and include a biopharma company with drug development for orphan diseases, a
medical device company targeting obesity and Paratek Pharmaceuticals, Inc. (NasdaqGM:PRTK),
which is crossing over in to the biodefense sector of homeland defense with its
antibiotic - omadacycline.
The latest tech companies are involved in the
wireless and Artificial Intelligence (AI) sectors, while the newest mining company
is involved in gold mining and geothermal projects in Guatemala.
New Biotech Companies Added:
Eiger BioPharmaceuticals, Inc. (NasdaqGM:EIGR) is a
clinical-stage biopharmaceutical company focused on the development and
commercialization of targeted therapies for orphan diseases. We are committed to translational innovation
and developing well-characterized drugs acting on newly identified or novel,
validated targets. Our mission is to
systematically reduce the time and cost of the drug development process to more
rapidly deliver important medicines to patients with orphan diseases.
Apollo Endosurgery, Inc. (NasdaqGM:APEN) is a
medical device company focused on less invasive therapies for the treatment of
obesity, a condition facing over 600 million people globally, as well as other
gastrointestinal disorders. Apollo’s device based therapies are an alternative
to invasive surgical procedures, thus lowering complication rates and reducing
total healthcare costs. Apollo's products are offered in over 80 countries
today.
Paratek Pharmaceuticals, Inc. (NasdaqGM:PRTK) is a biopharmaceutical company focused on the development and
commercialization of innovative therapies based upon its expertise in novel
tetracycline chemistry. The Company’s lead product candidate, omadacycline, is
a new, once-daily oral and intravenous broad-spectrum antibiotic being
developed for the treatment of serious community-acquired bacterial infections,
including community-acquired bacterial pneumonia (CABP), acute bacterial skin
and skin structure infections (ABSSSI), and urinary tract infections.
Omadacycline has been granted Qualified Infectious Disease Product designation
and Fast Track status by the U.S. Food and Drug Administration for the target
indications of ABSSSI, CABP, uUTI and cUTI. Paratek has completed Phase 3
development activities for omadacycline in CABP and ABSSSI and has initiated
its New Drug Application to the U.S. FDA in the United States. Paratek has
licensed rights for omadacycline to Zai Lab for the greater China region, and
retains all remaining global rights. Under a research agreement with the U.S.
Department of Defense, omadacycline also is being studied against pathogenic
agents causing infectious diseases of public health and biodefense importance,
including plague and anthrax. Paratek's second Phase 3 product candidate,
Seysara™ (sarecycline), is being developed by Allergan in the U.S. as a new
once-daily oral therapy for the treatment of acne. Allergan has completed Phase
3 development activities for Seysara and its new drug application was accepted
for review by the U.S. Food and Drug Administration in December 2017. Paratek
retains all ex-U.S. rights to Seysara.
New Tech Companies Added:
Casa Systems, Inc. (NasdaqGS:CASA)
provides software solutions that enable cable, wireless and wireline broadband
providers to meet the growing demand for gigabit bandwidth and services. We provide a suite of software-centric
infrastructure solutions that allow cable service providers to deliver voice,
video and data services over a single platform at multi-gigabit speeds. In
addition, we offer solutions for next-generation distributed and virtualized
architectures in cable operator, fixed telecom and wireless networks. Our solutions are commercially deployed in
over 70 countries serving more than 400 customers, including regional service
providers as well as some of the world’s largest Tier 1 broadband service
providers.
GWG Holdings,
Inc. (NasdaqCM:GWGH), the parent company of GWG Life and Life Epigenetics, is a financial
services company committed to transforming the life insurance industry through
disruptive and innovative products and services. GWG Life is developing a suite
of new longevity-based products for consumers and financial advisors under the
LifeCare Xchange (LCX) platform that provides consumers owning life insurance
the opportunity to exchange their policies for products that can be used to pay
for long-term care and other retirement financial needs. Life Epigenetics seeks
to further transform the industry by applying proprietary M-Panel epigenetic
technology to disrupt traditional life insurance underwriting practices. AI:
January 2018 - Dr. Olson will bring machine learning, artificial intelligence
and advanced data science to the company’s epigenetic technology that promises
to be transformational to life insurance underwriting.
New Mining Companies Added
Bluestone
Resources Inc. (TSX: BSR.V) is a mineral exploration and development company that
is focused on advancing its 100% owned Cerro Blanco gold and Mita geothermal
projects located in Guatemala. The Cerro Blanco Project economics, as disclosed
in the Company's Cerro Blanco Preliminary Economic Assessment which is
available at www.sedar.com, and updated mineral resource estimate for Cerro
Blanco indicates a robust project with an expected nine-year mine life producing
952,000 ounces of gold and 3,141,000 ounces of silver. Initial capital
expenditures estimated in the PEA to fund construction and commissioning is
estimated at US$170.8 million with all-in sustaining cash costs (as defined per
World Gold Council guidelines, less corporate general and administration costs)
estimated to be US$490 per ounce of gold produced.
The directories are not meant as recommendations
but as a research tool to discover opportunities and trading ideas in a
particular sector.
About
Investorideas.com - News that Inspires Big Ideas
www.Investorideas.com is a meeting place for global investors, featuring news, stock
directories, video, podcasts,
company profiles, interviews and more in leading sectors. Sectors we cover
include tech (AI, drones, internet of things) , payments, crypto and
blockchain, biotech, mining, energy, renewable energy, water , marijuana and
hemp stocks, food and beverage, defense and security (biometrics/cyber) ,Latin
America, sports, entertainment, luxury brands and gaming.
The Investorideas.com content portfolio goes beyond
the www.investorideas.com site to include 14 blogs on Blogger.com, 7
Artificial Intelligence (AI) websites on the Grid and the Waternewswire.com,
all featuring Investorideas.com news and content.
Investor Ideas Stock Directories for global investors:
From water stocks to gold and mining stocks,
renewable energy, nanotech, defense, technology, biotech and more – use our
stock directories and access them online 24/7 with login as a member to find
your next big idea!
Investorideas.com is also a CSE
service provider: http://thecse.com/en/services/services-for-listed-companies
Disclaimer/Disclosure: Investorideas.com is a
digital publisher of third party sourced news, articles and equity research as
well as creates original content, including video, interviews and articles.
Original content created by investorideas is protected by copyright laws other
than syndication rights. Our site does not make recommendations for purchases
or sale of stocks, services or products. Nothing on our sites should be
construed as an offer or solicitation to buy or sell products or securities.
All investment involves risk and possible loss of investment. This site is
currently compensated for news publication and distribution, social media and
marketing, content creation and more. Contact each company directly regarding
content and press release questions. Disclosure is posted for each compensated
news release, content published /created if required but otherwise the news was
not compensated for and was published for the sole interest of our readers and
followers. More disclaimer info: http://www.investorideas.com/About/Disclaimer.asp.
Additional info regarding BC Residents and global
Investors: Effective September 15 2008 - all BC investors should review all OTC
and Pink sheet listed companies for adherence in new disclosure filings and
filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894. Global investors must adhere to
regulations of each country.
Contact Investorideas.com
800-665-0411
